ACER3 and steatosis: Knocking out Acer3 was found to augment PEWD-induced elevation of C18:1-ceramide and alleviate early inflammation and fibrosis but not steatosis in mouse livers with NASH, suggesting that targeting ACER3 represents a novel approach to prevention and intervention of NASH 116.